Holen Sie sich die Stockscreener-App
0.4441
0.93%
0.0041
Handel nachbörslich:
.45
0.0059
+1.33%
Schlusskurs vom Vortag:
$0.44
Offen:
$0.44
24-Stunden-Volumen:
3.16M
Relative Volume:
0.53
Marktkapitalisierung:
$149.44M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.5921
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
+3.93%
1M Leistung:
-10.45%
6M Leistung:
-15.71%
1J Leistung:
-67.10%
1-Tages-Spanne:
$0.4368
$0.4587
1-Wochen-Bereich:
$0.406
$0.4597
52-Wochen-Spanne:
$0.3846
$1.51
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4441 | 148.06M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2026 world cup usa national team group stage playmakers transition play odds analysis insights - Улправда
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Revenue Check: Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure bill2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда
Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®
Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда
Is Sangamo Therapeutics Inc. stock a contrarian buyQuarterly Profit Summary & Precise Swing Trade Alerts - DonanımHaber
Can Sangamo Therapeutics Inc. stock attract ESG capital inflowsMarket Weekly Review & Low Drawdown Investment Strategies - DonanımHaber
Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com
Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus
Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat
Sangamo Therapeutics Earnings Notes - Trefis
Sangamo reports positive Fabry disease gene therapy results - MSN
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo receives U.S. FDA Fast Track Designation to ST-503 - MSN
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyLife Science Industry News - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Can Sangamo Therapeutics Inc. (GBY) stock attract analyst upgrades2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetPortfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
How reliable is Sangamo Therapeutics Inc. (GBY) stock dividend growth2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How Sangamo Therapeutics Inc. (GBY) stock reacts to fiscal policiesQuarterly Trade Review & Capital Efficient Trading Techniques - Newser
Fabry treatment ST-920 boosts kidney, heart function in trial - Fabry Disease News
Sangamo's hemophilia A gene therapy revenue forecasts cut after Pfizer exit - S&P Global
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA grants fast track designation for Sangamo’s pain treatment By Investing.com - Investing.com Canada
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Price Drop - 富途牛牛
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - marketscreener.com
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
Sangamo Therapeutics (SGMO) Stock Analysis Report | Financials & Insights - Benzinga
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):